L Johnson1, K M Winter, M Kwok, S Reid, D C Marks. 1. Applied and Developmental Research, Research and Development, Australian Red Cross Blood Service, Sydney, Australia.
Abstract
BACKGROUND AND OBJECTIVE: The Reveos automated blood processing system has been developed to combine primary and secondary processing of whole-blood units, resulting in a plasma unit, a red-blood-cell concentrate and an interim platelet unit per input. The aim of this study was to determine product specifications and in vitro quality of components produced by the Reveos system. MATERIALS AND METHODS: Whole blood was processed using the Reveos system and compared with historical Reference units produced using semi-automated methods. Reveos red cells were leucoreduced and stored in SAGM at 4°C. Reveos plasma was frozen at -30°C and factor activity was assessed after thawing. Reference red cell, plasma and buffy coats were produced by top and bottom processing. Leucoreduced Reveos and Reference platelet concentrates were prepared by pooling four interim platelet units or four buffy coats, respectively, with SSP+. RESULTS: Processing with the Reveos system was faster (76 min) than semi-automated separation (92 min). The red cell and platelet yields were higher in the units prepared by the Reveos system. The Reference and Reveos red cell and plasma units had very similar in vitro quality parameters. The platelet concentrates were also similar in many in vitro parameters, including pH, glucose and lactate metabolism, hypotonic shock response and phosphatidylserine expression, although platelet activation markers (CD62P and cytokine levels) were higher in the Reveos units. CONCLUSION: The Reveos system can improve blood component efficiencies through reductions in processing time, whilst maintaining similar component quality. Vox Sanguinis
BACKGROUND AND OBJECTIVE: The Reveos automated blood processing system has been developed to combine primary and secondary processing of whole-blood units, resulting in a plasma unit, a red-blood-cell concentrate and an interim platelet unit per input. The aim of this study was to determine product specifications and in vitro quality of components produced by the Reveos system. MATERIALS AND METHODS: Whole blood was processed using the Reveos system and compared with historical Reference units produced using semi-automated methods. Reveos red cells were leucoreduced and stored in SAGM at 4°C. Reveos plasma was frozen at -30°C and factor activity was assessed after thawing. Reference red cell, plasma and buffy coats were produced by top and bottom processing. Leucoreduced Reveos and Reference platelet concentrates were prepared by pooling four interim platelet units or four buffy coats, respectively, with SSP+. RESULTS: Processing with the Reveos system was faster (76 min) than semi-automated separation (92 min). The red cell and platelet yields were higher in the units prepared by the Reveos system. The Reference and Reveos red cell and plasma units had very similar in vitro quality parameters. The platelet concentrates were also similar in many in vitro parameters, including pH, glucose and lactate metabolism, hypotonic shock response and phosphatidylserine expression, although platelet activation markers (CD62P and cytokine levels) were higher in the Reveos units. CONCLUSION: The Reveos system can improve blood component efficiencies through reductions in processing time, whilst maintaining similar component quality. Vox Sanguinis
Authors: Ana Isabel Pérez Aliaga; Gorka Labata; Alfonso Aranda; Marcia Cardoso; Fernando Puente; José María Domingo; Carmen Garcés Journal: Transfus Med Hemother Date: 2021-06-09 Impact factor: 3.747
Authors: Sahra Fonseca; Marie-Pierre Cayer; K M Tanvir Ahmmed; Nima Khadem-Mohtaram; Steve J Charette; Danny Brouard Journal: Antibiotics (Basel) Date: 2022-01-14